Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Will People Accept Rampant Inflation? Hell, No!

The Weekly Missive, which usually arrives over the weekend (sometimes on Friday, sometimes on Sunday) was delayed this weekend for one reason: I had to change it. I started out last week with an idea that was leaning in the direction of full-on capitulation in the sen...
Streetwise Reports | June 24, 2020 |

Allakos Shares Double on AK002 Phase 2 Results and Earnings

Allakos Inc. shares are soaring today as the company reported Q2/19 earnings and announced positive results from its phase 2 study for its AK002 inhibitor used in the treatment of eosinophil and mast cell related diseases. Clinical stage biotech company Allak...
Streetwise Reports | August 7, 2019 |

Regeneron Reports Positive Phase 3 Dupixent Data; Gains EU Approval Recommendation

Regeneron Pharmaceuticals published positive results from two U.S. Phase 3 trials evaluating the safety and efficacy of Dupixent (dupilumab) in adults with recurring severe chronic rhinosinusitis with nasal polyps. The European Medicines Agency's Committee for Medicinal Produc...
Streetwise Reports | September 24, 2019 |

Price of Gold Fundamental Daily Forecast – Prices Tumble Amid Mixed Reaction to Coronavirus Scare

The “sluggish” forecast from the IMF likely means that central banks will keep interest rates at or near historically low levels. Furthermore, it opens the door to more creative central bank stimulus like Quantitative Easing (QE) and fresh fiscal stimulu...
FX Empire | January 21, 2020 |

Mylan Gets a Shot in the Arm with Pfizer Merger Deal

EpiPen manufacturer Mylan N.V. announced today that the company will merge with Pfizer Inc.'s Upjohn Division, which holds Pfizer's off-patent branded and generic drugs, forming a new company. Mylan Inc. (MYL:NASDAQ) and Pfizer Inc. (PFE:NYSE) today anno...
Streetwise Reports | July 31, 2019 |

Silver's Sharp Reaction Back

Technical analyst Clive Maund charts silver and explains why he believes it hasn't hit a final top. Silver reacted back sharply on Thursday and Friday after a parabolic blowoff top. This was not a final top, but it does indicate that silver needs to take a rest and co...
Streetwise Reports | September 10, 2019 |

Aquestive Therapeutics Shares Up on Pipeline Update and Raised Full-Year 2019 Guidance

Aquestive Therapeutics shares traded 20% higher today after the firm reported Q3/19 earnings and raised its FY/19 guidance. The firm states it expects to complete its NDA for Libervant buccal film near the end of this month. Yesterday afternoon, specialty pharmaceutic...
Streetwise Reports | November 7, 2019 |

FDA Approval of Peanut Allergy Treatment Expected Next Year

The current status, catalysts and outlook for the immunotherapy are discussed in a ROTH Capital Partners report. In a Nov. 7 research note, ROTH Capital Partners analyst Zegbeh Jallah reported that with respect to Aimmune Therapeutics Inc. (AIMT:NASDAQ) , "all eyes r...
Streetwise Reports | November 14, 2019 |

Pulmatrix's Licensing Deal with the JNJ Lung Cancer Initiative Sends Shares Up 100%

Pulmatrix's shares opened 90% higher today after the firm reported that it has signed a kinase inhibitor licensing agreement with the Lung Cancer Initiative at Johnson & Johnson. Prior to the U.S. markets open this morning on the first day of trading in 2020, clinical...
Streetwise Reports | January 3, 2020 |

Ocular Therapeutix Shares Climb More than 25% on Q4 Revenue and Phase 1 Wet AMD Clinical Data

Ocular Therapeutix shares set a new 52-week high price after the company reported preliminary FY/19 revenue results along with positive interim data from its Phase 1 clinical study of OTX-TKI for treatment of wet age-related macular degeneration. Ocular Ther...
Streetwise Reports | March 5, 2020 |
1 2 3 4 5 6 7 8 9 10 ...